Investors > News Releases
Jul 01, 2020
Myriad Launches New GeneSight® Psychotropic Patient Collection Kit
Products
Jun 25, 2020
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment
Pipeline
Jun 15, 2020
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National Provider
Products
Jun 11, 2020
Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare Beneficiaries
Pipeline
Jun 08, 2020
New Study Demonstrates GeneSight Psychotropic Better Predicts Blood Drug Levels When Compared to Single-Gene Testing
Products
Jun 04, 2020
Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer
Pipeline
May 29, 2020
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients
Pipeline
May 28, 2020
Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.
Corporate
May 26, 2020
Cerecor and Myriad Genetics Announce that Levels of Novel Cytokine, LIGHT Were Highly Correlated with Disease Severity and Mortality in COVID-19 ARDS Biomarker Study
Pipeline
May 20, 2020
Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer
Pipeline
May 11, 2020
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
Pipeline
May 05, 2020
Myriad Genetics Reports Fiscal Third-Quarter 2020 Financial Results
Financial
Apr 28, 2020
Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020
Corporate
Apr 20, 2020
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight® Psychotropic Test in People with Major Depressive Disorder
Pipeline
Apr 08, 2020
Myriad Withdrawing Financial Guidance for FY2020 Due to Business Impact from Coronavirus Pandemic
Financial